GRP stands for gastrin-releasing peptide, a small signaling molecule made up of 27 amino acids that plays roles throughout the body, from triggering stomach acid production to transmitting itch signals in the spinal cord. First identified in 1978 from pig stomach tissue, GRP belongs to a family of peptides closely related to bombesin, a compound originally found in frog skin. Despite its name suggesting a narrow digestive function, GRP turns up in the brain, lungs, prostate, and spinal cord, influencing everything from appetite to your internal body clock.
How GRP Works in the Digestive System
GRP earned its name because one of its most prominent jobs is stimulating the release of gastrin, a hormone that drives stomach acid production. Nerve cells lining the stomach and intestines produce, store, and release GRP. In the stomach, it comes from parasympathetic nerve fibers that respond to signals traveling down the vagus nerve, the major communication line between the brain and the gut.
Interestingly, these nerve endings don’t touch the gastrin-producing G cells directly. Instead, GRP drifts a short distance through the surrounding tissue to reach them, acting more like a local chemical messenger than a direct nerve signal. Once it arrives at a G cell, GRP locks onto a receptor on the cell surface. This receptor belongs to the G protein-coupled receptor family, meaning it triggers a chain of internal signals that ultimately cause the G cell to pump out gastrin, which then stimulates acid-secreting cells deeper in the stomach lining.
GRP’s effects on acid output appear to go beyond just boosting gastrin levels. In human studies, GRP influenced acid secretion independently of circulating gastrin, partly by enhancing the release of acetylcholine (another chemical messenger) from nearby neurons and by modulating somatostatin, a hormone that normally puts the brakes on acid production.
GRP and Appetite
Beyond digestion, GRP acts as a satiety signal. When healthy men received GRP through an IV at doses that mimic normal physiological effects, they ate significantly fewer calories and reported feeling full earlier than when they received a placebo. The effect was specific to food: fluid intake stayed the same, and there were no notable side effects. These findings confirmed what animal studies had already suggested, that GRP-related peptides help the body recognize when it has eaten enough.
The Itch Connection in the Spinal Cord
One of the more surprising discoveries about GRP is its central role in how you feel itch. In the spinal cord’s dorsal horn, a region that processes sensory information from the skin, GRP acts as the key chemical messenger that relays itch signals from one nerve cell to the next.
The process works through a gating mechanism. Nerve cells that detect itch-causing stimuli on the skin send signals to a group of spinal neurons that produce GRP. These GRP neurons don’t just fire once. They need to fire in sustained, repetitive bursts before the downstream neurons (which carry the GRP receptor) become activated. Single pulses of activity aren’t enough. Only when GRP accumulates from repeated bursts does it progressively depolarize the receiving neurons, essentially opening a gate that lets the itch signal travel upward to the brain. Blocking the GRP receptor on these downstream neurons prevents this activation entirely, which is why researchers have identified this pathway as a potential target for treating chronic itch conditions.
GRP in the Brain’s Internal Clock
Your body’s master clock sits in a tiny brain region called the suprachiasmatic nucleus, or SCN, which synchronizes daily rhythms in sleep, hormone release, and body temperature to the light-dark cycle. GRP-producing neurons cluster in the core region of the SCN and respond quickly to light hitting the retina.
When researchers measured calcium activity in these neurons (a proxy for how active they are), they found a sharp, transient spike in response to light exposure. This is distinct from neighboring neurons that use a different signaling molecule called VIP, which show a longer-lasting response. When GRP neurons in the SCN were artificially stimulated, they produced clear shifts in the animals’ daily activity rhythms: delays in the early night and advances in the late night, matching the pattern you’d expect from a system that helps reset the clock in response to light. That said, mice lacking GRP or these specific neurons still maintained normal circadian rhythms overall, suggesting GRP serves as an auxiliary fine-tuning mechanism rather than the clock’s essential driver.
GRP78: A Different Protein With a Similar Name
Searching for “GRP” can also lead to GRP78, a completely different molecule. GRP78 (also called BiP) is a 654-amino-acid protein that lives on the membrane of the endoplasmic reticulum, the cell’s protein-manufacturing hub. It belongs to the heat shock protein family and works as a molecular chaperone, meaning its job is quality control for newly made proteins.
When proteins fold incorrectly, GRP78 binds to them and either helps them refold into the right shape or tags them for destruction. Under normal conditions, GRP78 keeps three stress sensors on the endoplasmic reticulum membrane in an inactive state. When misfolded proteins pile up (a situation called ER stress), GRP78 releases those sensors to go deal with the problem. The sensors then activate a coordinated response that slows down new protein production and ramps up the cell’s folding and cleanup machinery. GRP78 is found in all organisms with complex cells, from yeast to humans, and its malfunction has been linked to cancer, neurodegenerative diseases, and metabolic disorders.
GRP as a Cancer Biomarker
GRP is produced by several types of cancer cells, particularly small cell lung cancer (SCLC), as well as some breast and prostate cancers. In these tumors, GRP can act as a growth factor that the cancer cells produce to stimulate their own proliferation.
A precursor form called pro-GRP (proGRP) has become a valuable blood test for detecting SCLC. At a cutoff of 63 pg/mL, proGRP identifies about 86% of SCLC cases while correctly ruling it out in 90% of people without the disease. The median proGRP level in SCLC patients is roughly 893 pg/mL, more than 14 times the diagnostic threshold. ProGRP rarely shows up elevated in other conditions, with the main exceptions being kidney problems, certain neuroendocrine tumors, and medullary thyroid cancer. This makes it one of the more reliable blood markers for distinguishing small cell lung cancer from other lung cancer types.
GRP Receptors as Therapeutic Targets
Because GRP receptors are abundant on certain tumor types, researchers are developing compounds that bind to these receptors for both imaging and treatment. Early work used receptor-activating compounds (agonists), but these caused unwanted side effects by switching on the receptor’s signaling. Newer approaches use antagonists, molecules that lock onto the receptor without activating it, which improves safety and imaging quality.
One such compound, a technetium-labeled antagonist called DB8, has completed Phase I clinical trials for imaging prostate cancer and shown encouraging early results in breast cancer patients. Administered as a single injection, it was well tolerated and produced images that could visualize GRP receptor expression in tumors. These imaging tools could eventually help doctors identify which patients have receptor-positive tumors and would benefit from GRP-targeted therapies.